In summary, miR-144 and DNAJC3-AS1 reciprocally regulate the doxorubicin sensitivity and apoptosis of breast cancer cells and provide new targets for improving the sensitivity of breast cancer cells to chemotherapy in the clinic. The gene discussed is DNAJC3; the disease is breast carcinoma.